UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Variants of uterine leiomyomas (fibroids)

Authors
Elizabeth A Stewart, MD
Bradley J Quade, MD, PhD
Shannon K Laughlin-Tommaso, MD
Section Editors
Robert L Barbieri, MD
Rochelle L Garcia, MD
Deputy Editor
Sandy J Falk, MD, FACOG

INTRODUCTION

Benign uterine leiomyomas (fibroids) are smooth muscle neoplasms of the myometrial layer of the uterus and are the most common pelvic tumor in women [1-3]. Less commonly, women with a uterine mass presumed to be a leiomyoma are found to have a uterine sarcoma or a leiomyoma variant. There are a number of leiomyoma variants in which the smooth muscle neoplasm manifests one histologic facet typical of malignant neoplasm, yet lacks others. Other variants are defined by their capacity to spread to other organs without invasion, and thus remains histologically benign. Finally, some smooth muscle neoplasm variants cannot be definitely classified and consequently are deemed to have an uncertain malignant potential. (See "Differentiating uterine leiomyomas (fibroids) from uterine sarcomas", section on 'Presumed benign leiomyomas'.)

Histologically and biologically defined variants of uterine leiomyomas are reviewed here. The diagnosis and management of ordinary uterine leiomyomas, as well as approaches to differentiating leiomyomas from uterine sarcomas, are discussed separately. (See "Uterine leiomyomas (fibroids): Epidemiology, clinical features, diagnosis, and natural history" and "Overview of treatment of uterine leiomyomas (fibroids)" and "Differentiating uterine leiomyomas (fibroids) from uterine sarcomas".)

CLINICAL APPROACH

Uterine fibroids (leiomyomas) are very common. In contrast, other myometrial smooth muscle variants are less frequent (approximately 1 to 2 percent in aggregate) and uterine sarcomas are rare (0.1 percent or less, depending on age) [4]. Differentiating between these, and thus providing appropriate evaluation and treatment, is clinically challenging.

Most leiomyoma variants present as presumed typical "fibroids" and are excised by gynecologists if they are symptomatic. The presence of an extrauterine mass makes it clear that this is a leiomyoma variant rather than a typical leiomyoma. Some of these cases come to attention as referrals when a woman with a thoracic mass initially presents to pulmonary or cardiovascular colleagues.

The rarity of leiomyoma variants limits epidemiologic study and, by extension, evidence-based guidance for diagnosis and treatment, especially for selected variant types that essentially are restricted to case reports and small case series. Most variants, being histologically defined, are diagnosed only after surgical removal; however, increasingly, abnormal magnetic resonance imaging (MRI) may suggest an atypical lesion, sometimes even prompting surgical excision.

                        
To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Nov 2017. | This topic last updated: Nov 28, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
References
Top
  1. Baird DD, Dunson DB, Hill MC, et al. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol 2003; 188:100.
  2. Buttram VC Jr, Reiter RC. Uterine leiomyomata: etiology, symptomatology, and management. Fertil Steril 1981; 36:433.
  3. Serden SP, Brooks PG. Treatment of abnormal uterine bleeding with the gynecologic resectoscope. J Reprod Med 1991; 36:697.
  4. Seidman JD, Thomas RM. Multiple plexiform tumorlets of the uterus. Arch Pathol Lab Med 1993; 117:1255.
  5. Mäkinen N, Vahteristo P, Kämpjärvi K, et al. MED12 exon 2 mutations in histopathological uterine leiomyoma variants. Eur J Hum Genet 2013; 21:1300.
  6. Buelow B, Cohen J, Nagymanyoki Z, et al. Immunohistochemistry for 2-Succinocysteine (2SC) and Fumarate Hydratase (FH) in Cutaneous Leiomyomas May Aid in Identification of Patients With HLRCC (Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome). Am J Surg Pathol 2016; 40:982.
  7. Sanz-Ortega J, Vocke C, Stratton P, et al. Morphologic and molecular characteristics of uterine leiomyomas in hereditary leiomyomatosis and renal cancer (HLRCC) syndrome. Am J Surg Pathol 2013; 37:74.
  8. Wheeler KC, Warr DJ, Warsetsky SI, Barmat LI. Novel fumarate hydratase mutation in a family with atypical uterine leiomyomas and hereditary leiomyomatosis and renal cell cancer. Fertil Steril 2016; 105:144.
  9. Garg K, Tickoo SK, Soslow RA, Reuter VE. Morphologic features of uterine leiomyomas associated with hereditary leiomyomatosis and renal cell carcinoma syndrome: a case report. Am J Surg Pathol 2011; 35:1235.
  10. Reyes C, Karamurzin Y, Frizzell N, et al. Uterine smooth muscle tumors with features suggesting fumarate hydratase aberration: detailed morphologic analysis and correlation with S-(2-succino)-cysteine immunohistochemistry. Mod Pathol 2014; 27:1020.
  11. Quade BJ, Robboy SJ. Uterine smooth muscle tumors. In: Robboy's Pathology of the Female Reproductive Tract, 2nd ed, Robboy SJ, Mutter GL, Prat J, et al (Eds), Churchill Livingstone Elsevier, Oxford 2009. p.474.
  12. Bell SW, Kempson RL, Hendrickson MR. Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases. Am J Surg Pathol 1994; 18:535.
  13. Lim D, Alvarez T, Nucci MR, et al. Interobserver variability in the interpretation of tumor cell necrosis in uterine leiomyosarcoma. Am J Surg Pathol 2013; 37:650.
  14. Perrone T, Dehner LP. Prognostically favorable "mitotically active" smooth-muscle tumors of the uterus. A clinicopathologic study of ten cases. Am J Surg Pathol 1988; 12:1.
  15. O'Connor DM, Norris HJ. Mitotically active leiomyomas of the uterus. Hum Pathol 1990; 21:223.
  16. Ip PP, Tse KY, Tam KF. Uterine smooth muscle tumors other than the ordinary leiomyomas and leiomyosarcomas: a review of selected variants with emphasis on recent advances and unusual morphology that may cause concern for malignancy. Adv Anat Pathol 2010; 17:91.
  17. Hodge JC, Quade BJ, Rubin MA, et al. Molecular and cytogenetic characterization of plexiform leiomyomata provide further evidence for genetic heterogeneity underlying uterine fibroids. Am J Pathol 2008; 172:1403.
  18. Moinfar F, Azodi M, Tavassoli FA. Uterine sarcomas. Pathology 2007; 39:55.
  19. Solomon LA, Schimp VL, Ali-Fehmi R, et al. Clinical update of smooth muscle tumors of the uterus. J Minim Invasive Gynecol 2005; 12:401.
  20. Evans HL, Chawla SP, Simpson C, Finn KP. Smooth muscle neoplasms of the uterus other than ordinary leiomyoma. A study of 46 cases, with emphasis on diagnostic criteria and prognostic factors. Cancer 1988; 62:2239.
  21. Oliva E, Carcangiu ML, Carinelli SG, et al. Chapter 5: Tumours of the uterine corpus: Mesenchymal tumors. In: WHO Classification of Tumours of Female Reproductive Organs, 4th ed, Kurman RJ, Carcangiu ML, Herrington CS, Young RH (Eds), International Agency for Research on Cancer, Lyon, France 2014. p.136.
  22. Giuntoli RL 2nd, Gostout BS, DiMarco CS, et al. Diagnostic criteria for uterine smooth muscle tumors: leiomyoma variants associated with malignant behavior. J Reprod Med 2007; 52:1001.
  23. Christacos NC, Quade BJ, Dal Cin P, Morton CC. Uterine leiomyomata with deletions of Ip represent a distinct cytogenetic subgroup associated with unusual histologic features. Genes Chromosomes Cancer 2006; 45:304.
  24. Ly A, Mills AM, McKenney JK, et al. Atypical leiomyomas of the uterus: a clinicopathologic study of 51 cases. Am J Surg Pathol 2013; 37:643.
  25. Taran FA, Weaver AL, Gostout BS, Stewart EA. Understanding cellular leiomyomas: a case-control study. Am J Obstet Gynecol 2010; 203:109.e1.
  26. Hodge JC, Kim TM, Dreyfuss JM, et al. Expression profiling of uterine leiomyomata cytogenetic subgroups reveals distinct signatures in matched myometrium: transcriptional profilingof the t(12;14) and evidence in support of predisposing genetic heterogeneity. Hum Mol Genet 2012; 21:2312.
  27. Hodge JC, Pearce KE, Clayton AC, et al. Uterine cellular leiomyomata with chromosome 1p deletions represent a distinct entity. Am J Obstet Gynecol 2014; 210:572.e1.
  28. Hardman WJ 3rd, Majmudar B. Leiomyomatosis peritonealis disseminata: clinicopathologic analysis of five cases. South Med J 1996; 89:291.
  29. Quade BJ, McLachlin CM, Soto-Wright V, et al. Disseminated peritoneal leiomyomatosis. Clonality analysis by X chromosome inactivation and cytogenetics of a clinically benign smooth muscle proliferation. Am J Pathol 1997; 150:2153.
  30. Halama N, Grauling-Halama SA, Daboul I. Familial clustering of Leiomyomatosis peritonealis disseminata: an unknown genetic syndrome? BMC Gastroenterol 2005; 5:33.
  31. Vaquero ME, Magrina JF, Leslie KO. Uterine smooth-muscle tumors with unusual growth patterns. J Minim Invasive Gynecol 2009; 16:263.
  32. Seidman MA, Oduyebo T, Muto MG, et al. Peritoneal dissemination complicating morcellation of uterine mesenchymal neoplasms. PLoS One 2012; 7:e50058.
  33. Ordulu Z, Dal Cin P, Chong WW, et al. Disseminated peritoneal leiomyomatosis after laparoscopic supracervical hysterectomy with characteristic molecular cytogenetic findings of uterine leiomyoma. Genes Chromosomes Cancer 2010; 49:1152.
  34. Worley MJ Jr, Aelion A, Caputo TA, et al. Intravenous leiomyomatosis with intracardiac extension: a single-institution experience. Am J Obstet Gynecol 2009; 201:574.e1.
  35. Andrade LA, Torresan RZ, Sales JF Jr, et al. Intravenous leiomyomatosis of the uterus. A report of three cases. Pathol Oncol Res 1998; 4:44.
  36. Fasih N, Prasad Shanbhogue AK, Macdonald DB, et al. Leiomyomas beyond the uterus: unusual locations, rare manifestations. Radiographics 2008; 28:1931.
  37. Buza N, Xu F, Wu W, et al. Recurrent chromosomal aberrations in intravenous leiomyomatosis of the uterus: high-resolution array comparative genomic hybridization study. Hum Pathol 2014; 45:1885.
  38. Sun C, Wang XM, Liu C, et al. Intravenous leiomyomatosis: diagnosis and follow-up with multislice computed tomography. Am J Surg 2010; 200:e41.
  39. Quade BJ, Dal Cin P, Neskey DM, et al. Intravenous leiomyomatosis: molecular and cytogenetic analysis of a case. Mod Pathol 2002; 15:351.
  40. Dal Cin P, Quade BJ, Neskey DM, et al. Intravenous leiomyomatosis is characterized by a der(14)t(12;14)(q15;q24). Genes Chromosomes Cancer 2003; 36:205.
  41. Castelli P, Caronno R, Piffaretti G, Tozzi M. Intravenous uterine leiomyomatosis with right heart extension: successful two-stage surgical removal. Ann Vasc Surg 2006; 20:405.
  42. García Rinaldi R, Pérez Hernández J, Corbalá AR, et al. Surgical treatment of multiple intracardiac and pulmonary artery tumor implants embolic from uterine intravascular leiomyomatosis. Bol Asoc Med P R 2007; 99:51.
  43. Wang J, Yang J, Huang H, et al. Management of intravenous leiomyomatosis with intracaval and intracardiac extension. Obstet Gynecol 2012; 120:1400.
  44. Bodner-Adler B, Bartl M, Wagner G. Intravenous leiomyomatosis of the uterus with pulmonary metastases or a case with benign metastasizing leiomyoma? Anticancer Res 2009; 29:495.
  45. Biri A, Korucuoglu U, Zumrutbas N, et al. Intravenous leiomyomatosis treated with aromatase inhibitor therapy. Int J Gynaecol Obstet 2008; 101:299.
  46. Grella L, Arnold TE, Kvilekval KH, Giron F. Intravenous leiomyomatosis. J Vasc Surg 1994; 20:987.
  47. Evans AT 3rd, Symmonds RE, Gaffey TA. Recurrent pelvic intravenous leiomyomatosis. Obstet Gynecol 1981; 57:260.
  48. Jautzke G, Müller-Ruchholtz E, Thalmann U. Immunohistological detection of estrogen and progesterone receptors in multiple and well differentiated leiomyomatous lung tumors in women with uterine leiomyomas (so-called benign metastasizing leiomyomas). A report on 5 cases. Pathol Res Pract 1996; 192:215.
  49. Awonuga AO, Shavell VI, Imudia AN, et al. Pathogenesis of benign metastasizing leiomyoma: a review. Obstet Gynecol Surv 2010; 65:189.
  50. Miller J, Shoni M, Siegert C, et al. Benign Metastasizing Leiomyomas to the Lungs: An Institutional Case Series and a Review of the Recent Literature. Ann Thorac Surg 2016; 101:253.
  51. Rivera JA, Christopoulos S, Small D, Trifiro M. Hormonal manipulation of benign metastasizing leiomyomas: report of two cases and review of the literature. J Clin Endocrinol Metab 2004; 89:3183.
  52. Patton KT, Cheng L, Papavero V, et al. Benign metastasizing leiomyoma: clonality, telomere length and clinicopathologic analysis. Mod Pathol 2006; 19:130.
  53. Motegi M, Takayanagi N, Sando Y, et al. [A case of so-called benign metastasizing leiomyoma responsive to progesterone]. Nihon Kyobu Shikkan Gakkai Zasshi 1993; 31:890.
  54. Reed WB, Walker R, Horowitz R. Cutaneous leiomyomata with uterine leiomyomata. Acta Derm Venereol 1973; 53:409.
  55. Alam NA, Bevan S, Churchman M, et al. Localization of a gene (MCUL1) for multiple cutaneous leiomyomata and uterine fibroids to chromosome 1q42.3-q43. Am J Hum Genet 2001; 68:1264.
  56. Stewart EA, Morton CC. The genetics of uterine leiomyomata: what clinicians need to know. Obstet Gynecol 2006; 107:917.
  57. Tomlinson IP, Alam NA, Rowan AJ, et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 2002; 30:406.
  58. Pollard P, Wortham N, Barclay E, et al. Evidence of increased microvessel density and activation of the hypoxia pathway in tumours from the hereditary leiomyomatosis and renal cell cancer syndrome. J Pathol 2005; 205:41.
  59. Pollard PJ, Brière JJ, Alam NA, et al. Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Hum Mol Genet 2005; 14:2231.
  60. Launonen V, Vierimaa O, Kiuru M, et al. Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc Natl Acad Sci U S A 2001; 98:3387.
  61. Toro JR, Nickerson ML, Wei MH, et al. Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am J Hum Genet 2003; 73:95.
  62. Lehtonen HJ, Kiuru M, Ylisaukko-Oja SK, et al. Increased risk of cancer in patients with fumarate hydratase germline mutation. J Med Genet 2006; 43:523.
  63. Alam NA, Rowan AJ, Wortham NC, et al. Genetic and functional analyses of FH mutations in multiple cutaneous and uterine leiomyomatosis, hereditary leiomyomatosis and renal cancer, and fumarate hydratase deficiency. Hum Mol Genet 2003; 12:1241.
  64. Bayley JP, Launonen V, Tomlinson IP. The FH mutation database: an online database of fumarate hydratase mutations involved in the MCUL (HLRCC) tumor syndrome and congenital fumarase deficiency. BMC Med Genet 2008; 9:20.
  65. D'Armiento J, Imai K, Schiltz J, et al. Identification of the benign mesenchymal tumor gene HMGA2 in lymphangiomyomatosis. Cancer Res 2007; 67:1902.
  66. Walker CL, Hunter D, Everitt JI. Uterine leiomyoma in the Eker rat: a unique model for important diseases of women. Genes Chromosomes Cancer 2003; 38:349.
  67. Bissler JJ, McCormack FX, Young LR, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008; 358:140.
  68. Taveira-Dasilva AM, Rabel A, Gochuico BR, et al. Prevalence of uterine leiomyomas in lymphangioleiomyomatosis. Fertil Steril 2011; 96:711.
  69. Pilarski R, Stephens JA, Noss R, et al. Predicting PTEN mutations: an evaluation of Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome clinical features. J Med Genet 2011; 48:505.
  70. Pilarski R. Cowden syndrome: a critical review of the clinical literature. J Genet Couns 2009; 18:13.
  71. Zhou J, Mochizuki T, Smeets H, et al. Deletion of the paired alpha 5(IV) and alpha 6(IV) collagen genes in inherited smooth muscle tumors. Science 1993; 261:1167.
  72. Segal Y, Peissel B, Renieri A, et al. LINE-1 elements at the sites of molecular rearrangements in Alport syndrome-diffuse leiomyomatosis. Am J Hum Genet 1999; 64:62.
  73. Quade BJ, Wang TY, Sornberger K, et al. Molecular pathogenesis of uterine smooth muscle tumors from transcriptional profiling. Genes Chromosomes Cancer 2004; 40:97.